Loading...
•
Mar 31, 2025
Abbott Q1 2025 Earnings Report
Abbott reported strong first-quarter results driven by double-digit EPS growth and solid performance in its Medical Devices segment.
Key Takeaways
Abbott delivered a solid Q1 2025 with 4.0% reported sales growth and adjusted EPS of $1.09. Net income rose to $1.33B, supported by strength in Diabetes Care and Structural Heart devices.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Abbott reaffirmed its full-year 2025 guidance, projecting adjusted EPS between $5.05 and $5.25 and organic sales growth of 7.5% to 8.5%.
Positive Outlook
- Full-year adjusted EPS guidance reaffirmed at $5.05–$5.25
- Expected organic sales growth of 7.5%–8.5%
- Strong momentum in Medical Devices, especially Diabetes Care
- New product rollouts in EU (Volt PFA System)
- Manufacturing expansions planned in Illinois and Texas
Challenges Ahead
- Diagnostics segment declined due to COVID-19 testing drop
- Headwinds from volume-based procurement programs in China
- Foreign exchange impact lowered reported growth by 2.8%
- Nutrition segment affected by discontinued product lines
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...